Answers are grounded in this paper and cite their sources.
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.
No takes yet. Share an insight, caveat, or question.
Patnaik et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: